Intracranial activity of tepotinib in patients (pts) with MET exon 14 (METex14) skipping NSCLC enrolled in VISION.

被引：6
|
作者：
Patel, Jyoti D.
Le, Xiuning
Veillon, Remi
Anderson, Ian Churchill
Bestvina, Christine M.
Demedts, Ingel
Garassino, Marina Chiara
Mazieres, Julien
Morise, Masahiro
Smit, Egbert F.
Eggleton, S. Peter
OBrate, Aurora
Otto, Gordon
Bruns, Rolf
Schumacher, Karl-Maria
Paik, Paul K.
机构：
[1] Northwestern Univ, Sch Med, Lurie Canc Ctr, Chicago, IL 60611 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] CHU Bordeaux, Serv Malad Resp, Bordeaux, France
[4] St Joseph Heritage Healthcare, Santa Rosa, CA USA
[5] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[6] AZ Delta, Roeselare, Belgium
[7] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[8] CHU Toulouse, Hop Larrey, Toulouse, France
[9] Nagoya Univ, Grad Sch Med, Dept Resp Med, Nagoya, Aichi, Japan
[10] Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands
[11] Merck KGaA, Global Clin Dev, Darmstadt, Germany
[12] Merck KGaA, Global Med Affairs, Darmstadt, Germany
[13] Merck KGaA, Dept Biostat, Darmstadt, Germany
[14] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.9084
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9084
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Tepotinib Safety in MET Exon 14 (METex14) Skipping NSCLC: Updated Results from the VISION Trial
    Veillon, R.
    Sakai, H.
    Le, X.
    Felip, E.
    Garassino, M. C.
    Cortot, A.
    Smit, E.
    Park, K.
    Griesinger, F.
    Britschgi, C.
    Wu, Y.
    Berghoff, K.
    Otto, G.
    Bruns, R.
    Paik, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S231 - S231
  • [22] Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: results from the VISION study and local UK experience
    Cui Wanyuan
    Brown, Nick
    Brown, Victoria
    Bulusu, Ramesh
    Denton, Arshi
    Evans, Joanne
    Forster, Martin
    Papadatos-Pastos, Dionysis
    Pellegrino, Loredana
    Walsh, Nessa
    Bruns, Rolf
    Otto, Gordon
    Paik, Paul
    LUNG CANCER, 2022, 165 : S38 - S39
  • [23] Tepotinib in patients with MET exon 14 (METex14) skipping advanced NSCLC: Updated efficacy results from VISION cohort A
    Sakai, Hiroshi
    Morise, Masahiro
    Felip, Enriqueta
    Veillon, Remi
    Garassino, Marina Chiara
    Raskin, Jo
    Viteri, Santiago
    Mazieres, Julien
    Cortot, Alexis B.
    Smit, Egbert
    Thomas, Michael
    Cho, Byoung Chul
    Conte, Pierfranco
    Yang, James Chih-Hsin
    Chen, Yuh-Min
    Park, Keunchil
    Gottfried, Maya
    Britschgi, Christian
    Le, Xiuning
    Paik, Paul
    ANNALS OF ONCOLOGY, 2021, 32 : S290 - S290
  • [24] Tepotinib in Patients with Advanced NSCLC with MET Exon 14 (METex14) Skipping: Overall Efficacy Results from VISION Cohort A
    Mazieres, J.
    Paik, P.
    Felip, E.
    Veillon, R.
    Sakai, H.
    Cortot, A.
    Viteri, S.
    Garassino, M.
    Van Meerbeeck, J.
    Raskin, J.
    Thomas, M.
    Morise, M.
    Cho, B. C.
    Conte, P.
    Bruns, R.
    Demuth, T.
    Schumacher, K. M.
    Le, X.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S5 - S5
  • [25] Tepotinib in Patients with MET exon 14 (METex14) Skipping Advanced NSCLC: Updated Efficacy Results from VISION Cohort A
    Paik, P.
    Sakai, H.
    Felip, E.
    Veillon, R.
    Garassino, M. C.
    Raskin, J.
    Viteri, S.
    Mazieres, J.
    Cortot, A.
    Smit, E.
    Thomas, M.
    Cho, B. C.
    Conte, P.
    Yang, J. C.
    Morise, M.
    Chen, Y.
    Park, K.
    Gottfried, M.
    Britschgi, C.
    Bruns, R.
    Otto, G.
    Johne, A.
    Le, X.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S174 - S174
  • [26] Activity of tepotinib in brain metastases (BM): Preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC
    Viteri, S.
    Mazieres, J.
    Veillon, R.
    Felip, E.
    Le, X.
    Garassino, M. C.
    Stanton, T. S.
    Morise, M.
    Lee, J-S.
    Matsumoto, S.
    De Marinis, F.
    Wehler, T.
    Clark, A.
    Friese-Hamim, M.
    Stroh, C.
    Bruns, R.
    Otto, G.
    Paik, P. K.
    ANNALS OF ONCOLOGY, 2020, 31 : S831 - S831
  • [27] Health-related quality of life (HRQoL) in patients (pts) with NSCLC harboring MET exon 14 skipping (METex14) treated with tepotinib
    Garassino, M. C.
    Le, X.
    Kowalski, D. M.
    Migliorino, M. R.
    Senellart, H.
    Pradera, J. Fuentes
    Walling, R.
    Kato, T.
    Thomas, M.
    Smit, E. F.
    Gottfried, M.
    Britschgi, C.
    Johne, A.
    Scheele, J.
    Bruns, R.
    Vioix, H.
    Pfeiffer, B.
    Paik, P. K.
    ANNALS OF ONCOLOGY, 2020, 31 : S864 - S864
  • [28] Activity of Tepotinib in Brain Metastases (BM): Preclinical and Clinical Data in MET Exon 14 (METex14) Skipping NSCLC
    Mazieres, J.
    Veillon, R.
    Felip, E.
    Le, X.
    Garassino, M. C.
    Stanton, T.
    Morise, M.
    Lee, J.
    Matsumoto, S.
    De Marinis, F.
    Wehler, T.
    Clark, A.
    Friese-Hamin, M.
    Stroh, C.
    Bruns, R.
    Otto, G.
    Paik, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S668 - S669
  • [29] Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC as Identified by Liquid (LBx) or Tissue (TBx) biopsy
    Felip, E.
    Garassino, M. C.
    Sakai, H.
    Le, X.
    Veillon, R.
    Smit, E.
    Mazieres, J.
    Cortot, A.
    Raskin, J.
    Thomas, M.
    Viteri, S.
    Iams, W.
    Kim, H. R.
    Yang, J.
    Stroh, C.
    Otto, G.
    Bruns, R.
    Paik, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1085 - S1086
  • [30] Health utility with tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC)
    Reinmuth, N.
    Popat, S.
    Paz-Ares, L.
    Knowles, E.
    Hatswell, A.
    McLean, T.
    Adrian, S.
    Gaumond, B.
    Vioix, H.
    Paik, P. K.
    ANNALS OF ONCOLOGY, 2021, 32 : S985 - S986
12345